In vivo proof of concept for Anticalins®
Advertisement
PIERIS Proteolab AG announced that one of its lead development candidates, Digical, completely neutralized lethal toxicity caused by an overdose of the cardiac steroid digoxin in a preclinical study. The dose of this Anticalin® was only approximately half the recommended dose of a marketed polyclonal antibody fragment product approved for the same purpose.
Recently, PIERIS has generated lipocalin muteins named Anticalins® against more than half a dozen protein targets with very high affinity and specificity. Now, the company has demonstrated therapeutic efficacy in a relevant preclinical model. This underlines the company's ability to generate development candidates from its proprietary Anticalin® technology platform. These Anticalins® are able to compete with antibodies.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous